I tried to buy some more shares the other day and could only get a quote on £500. There really aren't that many up for grabs at the moment.
Having said that, I'm not sure whether REC approval will give the SP a huge boost. I work in healthcare research and getting REC approval is admittedly (quite rightly) quite difficult on occasions. What is means is that you have managed to prove that the research that you want to carry out is accepted as being for the public good, ethically sound and that you have the right governance procedures in place. It's a long way from full product approval though.
Yes I've had that too. A bit confused to be honest!
My concern is the time needed at the moment. The way that I read it the judge was primarily objecting to the clarity of explanation of the scheme given the audience which means that an amount of time will need to be taken in re-drafting the communications and probably holding another vote. Patience is required here but I see it coming good in the end.
I think the possibility of integrated Network Behaviour Analysis and SIEM is definitely there, but the likes of IBM / Splunk are very entrenched in that market. There is also open source competition from Alienvault.
There clearly is an opportunity for a wide variety of products which is why they have managed to establish a foothold in the security market. I do see it as a limited market however.
On the flip side I would be happy to be proven wrong, but I think that will take another couple of years to play out.
I've worked in IT Security for a long time and here is my view on their technology. Please feel free to take it or ignore it.
The technology is clever. It is essentially behaviour analysis of network traffic. It learns what should be expected and then works out the probability that anything that it hasn't seen before is the result of some form of attack / security incident. However, SIEM technology such as Splunk / IBM QRadar does a similar job by looking at log files and log file management is a requirement for a properly run Information Security Framework. Network Behaviour analysis is not. I find it hard to justify both technologies (neither of which are cheap).
This isn't to say that there is no market for the technology, but I see it as limited. In theory they will be acquired for their IP by one of the larger fish at some point, but I can't convince myself to take a position right now.
May.11 -- Francisco Blanch, head of global commodities and derivatives research at Bank of America, is very bullish on copper. “We think we could go as high as $20,000 a ton if the supply of scrap copper doesn’t make it to the market," he told "Bloomberg Surveillance."
I like his thinking!
I don't think £8 is at all unreasonable. I seem to remember that 10 years ago we ran a poll on the EMED price and that would have been towards the bottom of the range of guesses. Don't forget that Touro is still sitting there while the price of copper is ticking up in addition to expansion of Rio Tinto.
The goodnews for usjust keeps on coming.
financialpost[dot]com/pmn/business-pmn/copper-at-10-year-high-on-supply-woes-prospects-of-demand-revival
Hi all
Happy Monday everyone. Read and chill!
Vaccine-dodging COVID variants biggest risk to markets - Deutsche Bank survey.
https://in(dot)investing(dot)com/news/update-1vaccinedodging-covid-variants-biggest-risk-to-markets--deutsche-bank-survey-2699166
It does put it into context when you talk about the current price only being the equivalent of 10p pre consolidation. I remember figures in excess of of 25-30p+ (now £6-8) being thrown round as quite reasonable expectations around 2009 on the old iii board. I once had a long chat with Ron Cuneen who was chief geologist at the time when I attended an investor event. To paraphrase what he said, the hard bit is getting everything up and running. One you have done that these mines can just go rolling on for decades with new exploration and proving up additional resource.
I invested then on the basis of the urbanisation of China pushing up copper prices. In truth, it's taken us a bit longer than I think anyone expected to get to where we are but I'm still convinced that my original reason for investing was good, and now we have electric vehicles coming on strong to boot!
I heard some interesting views from a Consultant who is linked to where I work.
In summary, they weren't convinced by LFTs in times of low prevalence or in low risk settings. The false negative rate when used by the public, in times of low prevalence, could be as high as 50%. The false positive is 3 false positives for every true.
They also had concerns about individuals use of LFT's in low risk / low prevalence environments, and this comes verbatim. "It is easy to motivated when swimming in a sea of Covid. Once the risk abates, not so much. Of my consultant colleagues, pretty much all of us were less than 100% compliant with testing by early April and unkeen to pick up the 2nd box."
Not wanting to rain on anyone's parade but please note that these are frameworks not orders. Yourgene have now effectively been approved as a company to purchase from under the framework at a discounted price. They now need to make sure that they win their fair share of contracts that are let by the purchasing organisations that are signed up to the framework.
Good news ... yes, but no big fat cigars should be lit just yet.
I have been involved in selling to government organisations in the past and you have to take into account what that framework actually is.
A framework is a buying tool for the public sector that means that i) Due diligence has already been done on those included in the tender and ii) hospitals etc that buy through the framework IN THEORY benefit from the buying power of the pricing detail that has been negotiated for the framework.
The public sector likes framework deals as it makes buying easy for the purchasing departments that are signed up to it and it makes pricing transparent to the purchaser.
However, there is usually no obligation on any organisation buying through the framework to buy a single unit. I am assuming that the £30billion is just the budget allocated to all of the items that it includes over the 4 year period.
The implication is that Novacyt have still got to get their sales and sales support teams out there and selling their socks off to benefit from the time and effort expended in getting onto the framework. The time and effort in both getting on the framework and indeed selling should not be underestimated!
I suspect that there will be a number of trial bake-offs against Thermo Fisher and perhaps other competitors that I may have missed between now and September with business landing form Q4 21 onwards.
Of course I may be talking utter nonsense but I don't think so.
Hi all
If you want to reassure yourself that your investment is sound just listen to the WHO's technical Covid lead:
https://edition.cnn.com/2021/04/13/world/who-coronavirus-reality-check-intl/index.html
It's a grim assessment of the situation but at least I may make a few quid from it.
TB
I agree and that would be a particularly difficult situation. Do you stand your ground and insist that current commitments are honoured at the risk of souring the relationship or show flexibility to maintain goodwill for the future? It's a tough call!
I just want some solid facts from Novacyt at the moment, not placatory / optimistic words from management or the “sky is falling” doom-mongering of those who want a cheaper entry point or genuinely think that Novacyt’s future just turned to the brown stuff.
…. and the sooner the better to be honest!